Chris Miller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chris Miller has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
G. Regev-Shoshani
Faculty of Medicine, Respiratory Division, University of British Columbia, Vancouver, British Columbia, Canada
3 shared publicationsBevin McMullin
Department of Respiratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
2 shared publicationsGilly Regev-Shoshani
Faculty of Medicine, Respiratory Division, University of British Columbia, Vancouver, British Columbia, Canada; Bovicor Pharmatech Inc., Vancouver, British Columbia, Canada
2 shared publicationsJ.S. Church
Department of Natural Resources, Thompson Rivers University, Kamloops, British Columbia, Canada
2 shared publicationsJeremy Road
Department of Respiratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
2 shared publications- Kevin C. Kain
University of Toronto
2 shared publications
Latest Publications
- 1 March 2017
- Published by Elsevier in Preventive Veterinary Medicine
- Vol. 138, 162-169
Non-inferiority of nitric oxide releasing intranasal spray compared to sub-therapeutic antibiotics to reduce incidence of undifferentiated fever and bovine respiratory disease complex in low to moderate risk beef cattle arriving at a commercial feedlot
- 1 March 2017
- Published by Elsevier in Preventive Veterinary Medicine
- Vol. 138, 162-169
Non-inferiority of nitric oxide releasing intranasal spray compared to sub-therapeutic antibiotics to reduce incidence of undifferentiated fever and bovine respiratory disease complex in low to moderate risk beef cattle arriving at a commercial feedlot
- 1 December 2016
- Published by Elsevier in Research in Veterinary Science
- Vol. 109, 21-28
Nitric oxide modulates the immunological response of bovine PBMCs in an in vitro BRDc infection model
- 1 December 2016
- Published by Elsevier in Research in Veterinary Science
- Vol. 109, 21-28
Nitric oxide modulates the immunological response of bovine PBMCs in an in vitro BRDc infection model
- Open Access
- 29 October 2015
- Published by Springer Nature in Malaria Journal
- Vol. 14 (1) , 1-11
Inhaled nitric oxide as adjunctive therapy for severe malaria: a randomized controlled trial
Severe malaria remains a major cause of childhood mortality globally. Decreased endothelial nitric oxide is associated with severe and fatal malaria. The hypothesis was that adjunctive inhaled nitric oxide (iNO) would improve outcomes in African children with severe malaria. A randomized, blinded, placebo-controlled trial of iNO at 80 ppm by non-rebreather mask versus room air placebo as adjunctive treatment to artesunate in children with severe malaria was conducted. The primary outcome was the longitudinal course of angiopoietin-2 (Ang-2), an endothelial biomarker of malaria severity and clinical outcome. One hundred and eighty children were enrolled; 88 were assigned to iNO and 92 to placebo (all received IV artesunate). Ang-2 levels measured over the first 72 h of hospitalization were not significantly different between groups. The mortality at 48 h was similar between groups [6/87 (6.9 %) in the iNO group vs 8/92 (8.7 %) in the placebo group; OR 0.78, 95 % CI 0.26–2.3; p = 0.65]. Clinical recovery times and parasite clearance kinetics were similar (p > 0.05). Methaemoglobinaemia >7 % occurred in 25 % of patients receiving iNO and resolved without sequelae. The incidence of neurologic deficits ( 0.05). iNO at 80 ppm administered by non-rebreather mask was safe but did not affect circulating levels of Ang-2. Alternative methods of enhancing endothelial NO bioavailability may be necessary to achieve a biological effect and improve clinical outcome. Trial Registration: ClinicalTrials.gov NCT01255215
- 29 October 2015
- Published by Springer Nature in Malaria Journal
- Vol. 14 (1) , 1-11
Open AccessInhaled nitric oxide as adjunctive therapy for severe malaria: a randomized controlled trial
Severe malaria remains a major cause of childhood mortality globally. Decreased endothelial nitric oxide is associated with severe and fatal malaria. The hypothesis was that adjunctive inhaled nitric oxide (iNO) would improve outcomes in African children with severe malaria. A randomized, blinded, placebo-controlled trial of iNO at 80 ppm by non-rebreather mask versus room air placebo as adjunctive treatment to artesunate in children with severe malaria was conducted. The primary outcome was the longitudinal course of angiopoietin-2 (Ang-2), an endothelial biomarker of malaria severity and clinical outcome. One hundred and eighty children were enrolled; 88 were assigned to iNO and 92 to placebo (all received IV artesunate). Ang-2 levels measured over the first 72 h of hospitalization were not significantly different between groups. The mortality at 48 h was similar between groups [6/87 (6.9 %) in the iNO group vs 8/92 (8.7 %) in the placebo group; OR 0.78, 95 % CI 0.26–2.3; p = 0.65]. Clinical recovery times and parasite clearance kinetics were similar (p > 0.05). Methaemoglobinaemia >7 % occurred in 25 % of patients receiving iNO and resolved without sequelae. The incidence of neurologic deficits ( 0.05). iNO at 80 ppm administered by non-rebreather mask was safe but did not affect circulating levels of Ang-2. Alternative methods of enhancing endothelial NO bioavailability may be necessary to achieve a biological effect and improve clinical outcome. Trial Registration: ClinicalTrials.gov NCT01255215
- 1 April 2014
- Published by Elsevier in Research in Veterinary Science
- Vol. 96 (2) , 328-337
Safety, bioavailability and mechanism of action of nitric oxide to control Bovine Respiratory Disease Complex in calves entering a feedlot
- 1 April 2014
- Published by Elsevier in Research in Veterinary Science
- Vol. 96 (2) , 328-337
Safety, bioavailability and mechanism of action of nitric oxide to control Bovine Respiratory Disease Complex in calves entering a feedlot
- 1 December 2013
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 12 (6) , 817-820
Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumonia
- 1 December 2013
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 12 (6) , 817-820
Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumonia
- 1 May 2013
- Published by Elsevier in Nitric Oxide
- Vol. 31, 48-53
Gaseous nitric oxide reduces influenza infectivity in vitro
- 1 May 2013
- Published by Elsevier in Nitric Oxide
- Vol. 31, 48-53
Gaseous nitric oxide reduces influenza infectivity in vitro
- Open Access
- 22 October 2012
- Published by Oxford University Press (OUP) in Journal of Applied Microbiology
- Vol. 114 (2) , 536-544
A nitric oxide-releasing solution as a potential treatment for fungi associated with tinea pedis
Aims To test a nitric oxide-releasing solution (NORS) as a potential antifungal footbath therapy against Trichophyton mentagrophytes and Trichophyton rubrum during the mycelial and conidial phases. Methods and Results NORS (sodium nitrite citric acid) produces nitric oxide verified by gas chromatography and mass spectrometry (GC-MS). Antifungal activity of this solution was tested against mycelia and conidia of T. mentagrophytes and T. rubrum, using 1–20 mmol l−1 nitrites and 10–30 min exposure times. The direct effect of the gas released from the solution on the viability of those fungi was tested. NORS demonstrated strong antifungal activity and was found to be dose and time dependent. NO and nitrogen dioxide (NO2) were the only gases detected from this reaction and are likely responsible for the antifungal effect. Conclusions This in vitro research suggests that a single 20-min exposure to NORS could potentially be used as an effective single-dose treatment against fungi that are associated with tinea pedis in both mycelia and spore phase. Significance and Impact of the Study This study provides the background for developing a user-friendly footbath treatment for Athlete's Foot that will kill both vegetative fungi and its spores.
- 22 October 2012
- Published by Oxford University Press (OUP) in Journal of Applied Microbiology
- Vol. 114 (2) , 536-544
Open AccessA nitric oxide-releasing solution as a potential treatment for fungi associated with tinea pedis
Aims To test a nitric oxide-releasing solution (NORS) as a potential antifungal footbath therapy against Trichophyton mentagrophytes and Trichophyton rubrum during the mycelial and conidial phases. Methods and Results NORS (sodium nitrite citric acid) produces nitric oxide verified by gas chromatography and mass spectrometry (GC-MS). Antifungal activity of this solution was tested against mycelia and conidia of T. mentagrophytes and T. rubrum, using 1–20 mmol l−1 nitrites and 10–30 min exposure times. The direct effect of the gas released from the solution on the viability of those fungi was tested. NORS demonstrated strong antifungal activity and was found to be dose and time dependent. NO and nitrogen dioxide (NO2) were the only gases detected from this reaction and are likely responsible for the antifungal effect. Conclusions This in vitro research suggests that a single 20-min exposure to NORS could potentially be used as an effective single-dose treatment against fungi that are associated with tinea pedis in both mycelia and spore phase. Significance and Impact of the Study This study provides the background for developing a user-friendly footbath treatment for Athlete's Foot that will kill both vegetative fungi and its spores.
- 1 July 2012
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 11 (4) , 324-331
A phase I clinical study of inhaled nitric oxide in healthy adults
- 1 July 2012
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 11 (4) , 324-331
A phase I clinical study of inhaled nitric oxide in healthy adults